Mental Activity Helps to Lower Risk of Alzheimer’s Disease

Taken directly from the Rush Memory and Aging Project news release.

How often older adults read a newspaper, play chess, or engage in other mentally stimulating activities is related to the risk of developing Alzheimer’s disease, according to a study by researchers at Rush University Medical Center.

Taken directly from the Rush Memory and Aging Project news release.


Frequent Brain Stimulation in Old Age Reduces Risk of Alzheimer’s Disease


(CHICAGO) – How often older adults read a newspaper, play chess, or engage in other mentally stimulating activities is related to the risk of developing Alzheimer’s disease, according to a study by researchers at Rush University Medical Center published June 27 in the online edition of Neurology®, the medical journal of the American Academy of Neurology.

For the study, more than 700 people in Chicago with an average age of 80 underwent yearly cognitive testing for up to five years. Participants were part of the Rush Memory and Aging Project, a longitudinal study of more than 1,200 older people. Of the participants, 90 developed Alzheimer’s disease. Researchers also performed a brain autopsy on the 102 participants who died.

The study found that a cognitively active person in old age was 2.6 times less likely to develop dementia and Alzheimer’s disease than a cognitively inactive person in old age. This association remained after controlling for past cognitive activity, lifetime socioeconomic status, and current social and physical activity.

Researchers say the findings may be used to help prevent Alzheimer’s disease.

“Alzheimer’s disease is among the most feared consequences of old age,” said study author Robert S. Wilson, PhD, a neuropsychologist at the Rush Alzheimer’s Disease Center. “The enormous public health problems posed by the disease are expected to increase during the coming decades as the proportion of old people in the United States increases. This underscores the urgent need for strategies to prevent the disease or delay its onset.”

Wilson says the study also found frequent cognitive activity during old age such as visiting a library or attending a play, was associated with reduced risk of mild cognitive impairment, a transitional stage between normal aging and dementia, and less rapid decline in cognitive function.

The study was supported by grants from the National Institute on Aging and the Illinois Department of Public Health.

The Rush Alzheimer's Disease Center is one of 29 NIA-supported Alzheimer's Disease Centers across the U.S. which conduct basic science, clinical, and social and behavioral research on dementia and AD. General information on aging and aging research can be viewed at the NIA's home website, www.nia.nih.gov. For more information on the Rush Alzheimer’s Disease Center, visit www.rush.edu.



The Emotional Survival Guide for Caregivers: Looking After Yourself and Your Family While Helping an Aging Parent


"ACTIONALZ.ORG", alzheimer's disease, blog, brain, stimulation, caregiver, care giving, chess, mental-health, National Institute on Aging, neurology, prevent, Rush University Medical Center

Clinical Trial: Omega 3 Fatty Acid, Slowing the Progression of Alzheimer's Disease

Preliminary studies have shown a reduced risk of Alzheimer's disease (AD) in people consuming increased amounts of fish in their diets. Many of the health benefits of fish are attributed to the abundance of omega 3 fatty acids. Docosahexaenoic Acid (DHA) is the most abundant omega 3 fatty acid in the brain. Data from several animal models supports the hypothesis that DHA may be an effective treatment for AD by means of anti-amyloid, antioxidant, and neuroprotectant mechanisms.

This study is currently recruiting patients.

Personal Note: I have been feeding my mother fish and giving her Omega 3 Oil daily for a couple of years. I believe it is beneficial.

For a complete description of the trial including eligibility requirements go to the Clinical Trials Page

Official Title: A Randomized Double-Blind Placebo-Controlled Trial Of The Effects Of Docosahexaenoic Acid (DHA) In Slowing The Progression Of Alzheimer’s Disease

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Further study details as provided by National Institute on Aging (NIA)

Primary Outcome Measures:
Changes in rate of cognitive and functional decline measured by ADAS-Cog and CDR-SOB

Preliminary studies have shown a reduced risk of Alzheimer's disease (AD) in people consuming increased amounts of fish in their diets. Many of the health benefits of fish are attributed to the abundance of omega 3 fatty acids. Docosahexaenoic Acid (DHA) is the most abundant omega 3 fatty acid in the brain. Data from several animal models supports the hypothesis that DHA may be an effective treatment for AD by means of anti-amyloid, antioxidant, and neuroprotectant mechanisms.

In this study, 400 individuals with mild to moderate AD will participate at approximately 53 study sites throughout the US for 18 months. Participants will be randomized so that 60% will receive approximately 2 grams of DHA, divided into 4 capsules, 2 capsules taken twice a day, while 40% receive an identical placebo.

Potential participants will go to their study site for a screening visit, where eligibility is determined, and if accepted, for a baseline visit where cognitive status, behavioral status, functional status, and global severity of dementia will be assessed. Vital signs and biomarker labs will also be obtained. Subsequent visits will occur every three months for medication checks and, every 6 months, further assessments, physical exams, and labs.

Some participants will also take part in MRI (magnetic resonance imaging) and/or CSF (cerebrospinal fluid) sub-studies. For the MRI sub-study, scans will be done prior to beginning the study medication, and again after 18 months. Likewise, for the CSF sub-study, a lumbar puncture will be done prior to beginning the study medication, and again after 18 months.

Enrollment is restricted to individuals who consume no more than 200 mg of DHA per day, which is almost 300% of the average daily intake in an American diet. Individuals who take fish oil or omega 3 fatty acid supplements are also not eligible. Each visit will include completion of a very brief food frequency questionnaire to monitor dietary DHA levels.

Risk Evaluation and Education for Alzheimer's Disease

REVEAL, the Risk Evaluation and Education for Alzheimer's Disease— Study is a multi-center funded research project.

The goal of REVEAL is to provide healthy adults with genetic susceptibility testing and information about their chances to develop Alzheimer's disease.

Genetics and Alzheimer's Risk

More at the Alzheimer's Reading Room,

The National Public Health Road Map to Maintaining Cognitive Health (Road Map)

Download the The Healthy Brain Initiative

A National Public Health Road Map to Maintaining Cognitive Health.

The Healthy Brain Initiative

The Healthy Brain Initiative

Myriad Genetics (MYGN) Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimer's Conference

Current Flurizan™ Phase 3 Study Design May Demonstrate Disease Modification

Read the entire release at The Alzheimer's Reading Room

myriad genetics
"staggered start"
Alzheimer's Association Prevention Conference
disease modification
Flurizan Phase 3

The 36-Hour Day: A Family Guide to Caring for People with Alzheimer Disease, Other Dementias, and Memory Loss in Later Life

This best-selling book is the "bible" for families caring for people with Alzheimer disease...



Read the full text review at The Alzheimer's Reading Room

Americans Fear Alzheimer’s More Than Heart Disease, Diabetes or Stroke

A recent study by the MetLife Foundation found that Americans fear getting Alzheimer's disease more than heart disease, stroke, or diabetes. Alzheimer's ranks second in the minds of American's only to cancer.

Read this at the Alzheimer's Reading Room, The: Americans Fear Alzheimer’s More Than Heart Disease, Diabetes or Stroke

Fruit Smoothie Could Improve Thinking, Memory In Alzheimer's Patients

This article on the smoothie really caught my attention. Why? I drink one of those almost every day. Oddly, when I try to get my mother, the Alzheimer's patient, to drink one along with me she refuses.

A simple fruit smoothie could soon help improve thinking and memory in Alzheimer's patients.



Fruit Smoothie Could Improve Thinking, Memory In Alzheimer's Patients

St. Louis University is the only U.S test center to study whether the drink actually works. The beverage isn't a new drug, but a nutritional drink with a combination of vitamins, antioxidants and lipids that are consumed once a day. The smoothie comes in peach or cappuccino flavors.

Dr. Theodore Malmstrom is one of three researchers looking into what could soon be a very important weapon in the fight against Alzheimer's.

"There is increasing evidence that concentrated components of natural foods can improve memory so those components have been put in a drink and we are hopeful it will help," said Malmstrom.

The goal now is to get actual patients to test it out.

SLU researchers need at least 10 Alzheimer's patients to take part in the study. They are looking for people recently diagnosed with Alzheimer's, but not currently taking medications.

Patients will be divided in two groups. One group will get a daily supply of drinks with nutritional supplements. The other group will get a similar drink but without the nutritional additions.

Results of the 24-week study will hopefully end with good news.

"There is always great hope whenever you can have new research emerging. One of the Alzheimer's Associations mission (is) to fund research programs so we are very excited," said Stephanie Rohlfs-Young, the outreach director for the St. Louis Chapter of the Alzheimer's Association.

The risk of side effects from the drink are very minor compared to side effects from the five FDA-approved medications that treat Alzheimer's.

For more information, contact Malmstrom at 314-577-8745.

2007 Alzheimer’s Disease Facts and Figures

The links provided below will take you to the factsheets and full report published by the Alzheimer's Association.

Quote Sheet (2 pages)

FactSheet (2 pages)

2007 Alzheimer’s Disease Facts and Figures (28 pages)

The CareGiver Blog

Robert T DeMarco

AllAmerican Senior Care

AllAmerican Senior Care Weblog

Senior CareElder CareCareGiver Alzheimer’sDementia> CareGiver

Alzheimer's Disease Rate Rises to More Than Five Million in the United States

Someone Develops Alzheimer's Every 72 Seconds, According To New Alzheimer's Association Report.

The Alzheimer’s Association today reports that in 2007 there are now more than 5 million people in the United States living with Alzheimer’s disease. This number includes 4.9 million people over the age of 65 and between 200,000 and 500,000 people under age 65 with early onset Alzheimer’s disease and other dementias.


Read more about this topic at The Alzheimer's Reading Room

Many Alzheimer's caregivers seek help in God

About a third of those who take care of loved ones with the disease feel 'more religious' because of their experiences, a new national study says.


You can read this article at The CareGiver Weblog

The Alzheimer's Reading Room Weblog: Trouble identifying odors points to Alzheimer’s

One thing I noticed a long time ago was that my mother's sense of smell was gone. I am always looking for ways to take better care of myself and of course to detect any symptoms of Alzheimer's in myself and other members of my family. By now you might guess that I will be paying close attention to my ability to detect odors.

Dr. Robert S. Wilson told Reuters Health that difficulty identifying odors seems to be related the buildup of 'tangles' in the brain that appear early in the development of Alzheimer’s disease. “We found the correlation of difficulty identifying familiar odors with Alzheimer’s disease pathology even in people without dementia,” he added.


Go read the entire article at The Alzheimer's Reading Room Weblog: Trouble identifying odors points to Alzheimer’s

Exercise slows decline in Alzheimer's patients

I can attest, exercise makes a difference. My mother now has the tendency to sit around all day. On those days when I can get her to go to Gold's Gym with me she is a completely different person. The look on her face, from dull to smiling, is more than enough to tell me that exercise works to her benefit.

"Nursing home residents with Alzheimer's disease who participate in a moderate exercise program have a significantly slower deterioration than those who receive routine medical care, researchers have shown."

Read the article in its entirety at the CareGiver: The Book Weblog

Myriad Genetics Presents Additional Flurizan Phase 2 Study Data

Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) announced today that it presented additional results of its completed Phase 2 follow-on study of Flurizan™ in patients with mild Alzheimer's disease at the annual meeting of the American Association for Geriatric Psychiatry (AAGP), held March 1-4, 2007 in New Orleans.

Read the release in its entirety at The Alzheimer's Reading Room Weblog

Loneliness Increases Risk for ALzheimer's Disease-Like Dementia

"Social isolation in old age has been associated with risk of developing dementia, but the risk associated with perceived isolation, or loneliness, is not well understood," write Robert S. Wilson, PhD, of the Rush University Medical Center in Chicago, Illinois, and colleagues. "We examined these issues using data from the Rush Memory and Aging Project, a longitudinal clinicopathologic study of risk factors for chronic conditions of old age."



Source Medscape

Lonely elderly patients are more than twice as likely to develop Alzheimer's disease (AD)-like dementia than those who are not lonely, according to the results of a 4-year cohort study reported in the February issue of the Archives of General Psychiatry. However, pathology did not reveal Alzheimer's disease or cerebral infarction, suggesting that novel mechanisms may be involved.

"Social isolation in old age has been associated with risk of developing dementia, but the risk associated with perceived isolation, or loneliness, is not well understood," write Robert S. Wilson, PhD, of the Rush University Medical Center in Chicago, Illinois, and colleagues. "We examined these issues using data from the Rush Memory and Aging Project, a longitudinal clinicopathologic study of risk factors for chronic conditions of old age."

At baseline and annually thereafter for up to 4 years, 823 participants recruited from senior citizen facilities in and around Chicago, underwent uniform in-home evaluations including detailed cognitive function testing, clinical classification of dementia and AD, and assessment of loneliness with a modified version of the de Jong-Gierveld Loneliness Scale. For participants who died, uniform postmortem evaluation of the brain quantified AD pathologic abnormalities and cerebral infarction.

On the 5-item loneliness scale, mean baseline score was 2.3 ± 0.6. During follow-up, 76 subjects developed clinical AD, based on previously established composite measures of global cognition and specific cognitive functions.

Compared with persons who were not lonely (score, 1.4; 10th percentile), risk for AD was more than doubled in lonely persons (score, 3.2; 90th percentile). Controlling for indicators of social isolation did not affect this finding. Loneliness was associated with lower level of cognition at baseline and with more rapid cognitive decline during follow-up. There was no significant change in loneliness during the study, and mean degree of loneliness was robustly associated with cognitive decline and with development of clinical AD.

In 90 participants who died and had brain autopsy, loneliness was unrelated to summary measures of AD pathology or to cerebral infarction.

"Loneliness is associated with an increased risk of late-life dementia but not with its leading causes," the authors write.

Study limitations include predominantly white volunteer cohort, mean observation period less than 3 years, only 76 cases of incident AD, and only 90 autopsies performed.

"The perception of being alone was associated with cognitive decline and development of an AD-like dementia even after controlling for objective indexes of social isolation and other covariates," the authors conclude. "Neither AD pathology nor cerebral infarction could account for the association, suggesting that novel neurobiologic mechanisms may be involved."

The National Institute on Aging and the Illinois Department of Public Health supported this study. The authors have disclosed no relevant financial relationships.

Arch Gen Psychiatry. 2007;64:234-240.

Clinical Context

Little is known about the association of dementia and emotional isolation, although social isolation, defined as having a small social network, being unmarried, and participating in few activities with others, has been associated with increased risk for dementia.

This is a prospective cohort study within the Rush Memory and Aging Project, a longitudinal clinicopathologic study of risk factors for chronic diseases of old age. Loneliness was assessed using a modified version of the de Jong-Gierveld Loneliness Scale, and patients were followed up for incidence of AD and cognitive impairment, and brain autopsies were performed at death.

Study Highlights

Inclusion criteria were absence of dementia and living in retirement communities, subsidized housing, local churches, or social services agencies.
At baseline, all participants underwent structured history, cognitive testing, and comprehensive assessment for AD.
The criteria for AD were from the joint working group of the National Institute of Neurological and Communicative Disease Disorders and Stroke-Alzheimer Disease and Related Disorders Association.
A modified version of the de Jong-Gierveld Loneliness Scale with a 5-point Likert scale was used for self-reported symptoms of loneliness.
Social isolation was assessed by social network size and frequency of participation in social activity, rated on a 5-point scale.
Depressive symptoms were assessed with a 10-item form by the Center for Epidemiological Studies–Depression scale for 9 cognitive activities.
Physical functioning was assessed using the Health Interview Survey.
At each annual evaluation thereafter, 20 cognitive tests were administered including the Mini-Mental State Examination and 19 tests with 7 measures of episodic memory.
A composite measure based on all 19 test results was used to quantify cognitive decline.
Postmortem brain autopsy was performed in subjects who died.
857 subjects completed at least one follow-up evaluation.
Mean follow-up period was 3 years.
Mean age was 81 years, 76% were women, mean years of education was 14 years, 91% were white, 66% lived in retirement homes, 30% in single family homes, and 4% in assisted-living settings.
Loneliness was negatively correlated to social network size, frequency of social activity, and cognitive activity and education.
76 subjects developed dementia that met AD criteria.
Those who developed AD were older, more likely to be men, had lower cognitive function, lower income, and higher levels of loneliness and disability.
The risk for AD increased by 51% for each point on the loneliness scale (relative risk [RR], 1.51).
A person with a high degree of loneliness (90th percentile for score) was 2.1 times more likely to develop clinical AD compared with someone with a low degree of loneliness (10th percentile for score).
More frequent social activity was associated with reduced AD risk (RR, 0.52).
Loneliness was inversely related to level of cognitive activity.
The association of loneliness with AD was unchanged after adjustment for race, income, disability, and vascular risk factors.
Loneliness was inversely related to baseline level of function on each cognitive measure.
Loneliness was associated with more rapid decline in global cognition, semantic memory, perceptual speed, and visuospatial ability.
There was no significant change in loneliness during the study.
135 subjects died, and brain autopsy was performed on 90 subjects.
Baseline loneliness score was unrelated to a global measure of AD pathology identified by silver stain, percentage area occupied by amyloid plaques, and density of neurofibrillary tangles.
The authors concluded that the association between loneliness and AD or cognitive decline was not mediated by AD pathology or cerebral infarction.

Pearls for Practice

In elderly persons, those with loneliness vs those without loneliness have an increased risk for AD-like dementia.
Loneliness is not related to AD pathologic findings or cerebral infarction.

The CareGiver Blog

Robert T DeMarco

AllAmerican Senior Care

Senior CareElder CareCareGiver Alzheimer’sDementia> CareGiver

New Drug Stops Alzheimer's In Tracks

New Drug Stops Alzheimer's In Tracks

Caring for the CareGivers

“I don’t think I know how to handle the situation with dementia,” she said about her husband’s disease, diagnosed 10 years ago. “I lose my temper a lot and I get exasperated. I know I’m not handling things well, not for him and not for myself.”

Read the article in its entirety Caring for the CareGivers

Loneliness and Alzheimer's Linked

"People who are lonely are twice as likely to develop Alzheimer's disease, a large US study has suggested."

Read this article at The Senior Reading Room

Huperzine A in Alzheimer's Disease-The Clinical Trial

"The Huperzine A in Alzheimer's Disease clinical trial is currently open and recruiting patients. This is a Phase II clinical trial."

Read about the study including requirements and available locations at The Alzheimer's Reading Room: Huperzine A in Alzheimer's Disease-The Clinical Trial.

Alzheimer's Vaccine Patch Works in Mice

"The Alzheimer's vaccine being tested works by triggering the immune system to recognize and attack Ab -- a protein that abnormally builds up in the brains of Alzheimer's patients."

Read the entire article Alzheimer's Vaccine Patch Works in Mice